Today, Protagonist Therapeutics Inc (PTGX) Lowered by The Zacks Investment Research

Today, Protagonist Therapeutics Inc (PTGX) Lowered by The Zacks Investment Research

Zacks Investment Research downgraded shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) from a hold rating to a sell rating in a report issued on Thursday morning.

According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

Several other equities research analysts have also commented on the stock. BMO Capital Markets started coverage on shares of Protagonist Therapeutics in a research report on Tuesday, September 6th. They set an outperform rating for the company. Leerink Swann started coverage on shares of Protagonist Therapeutics in a research report on Tuesday, September 6th. They set an outperform rating and a $17.00 price target for the company. Finally, Barclays PLC started coverage on shares of Protagonist Therapeutics in a research report on Tuesday, September 6th. They set an overweight rating and a $18.00 price target for the company.

Protagonist Therapeutics (NASDAQ:PTGX) opened at 25.01 on Thursday. The stock’s market capitalization is $418.02 million. Protagonist Therapeutics has a 1-year low of $10.02 and a 1-year high of $25.60. The firm’s 50 day moving average is $22.06 and its 200 day moving average is $18.12.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by $0.29. During the same quarter in the previous year, the firm earned ($12.79) EPS.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Credit Suisse AG bought a new position in shares of Protagonist Therapeutics during the third quarter worth about $358,000. Northern Trust Corp bought a new position in shares of Protagonist Therapeutics during the third quarter worth about $425,000. Spark Investment Management LLC bought a new position in shares of Protagonist Therapeutics during the third quarter worth about $889,000. BVF Inc. IL bought a new position in shares of Protagonist Therapeutics during the third quarter worth about $7,924,000. Finally, RA Capital Management LLC bought a new position in shares of Protagonist Therapeutics during the third quarter worth about $15,941,000.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist’s primary focus is on developing oral peptide drugs that specifically target biological pathways.

Related posts

Leave a Comment